- Home
- ARQT vs OCUL Comparison
ARQT vs OCUL Comparison
Compare ARQT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- OCUL
- Stock Information
- Founded
- ARQT 2016
- OCUL 2006
- Country
- ARQT United States
- OCUL United States
- Employees
- ARQT N/A
- OCUL N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- OCUL Health Care
- Exchange
- ARQT Nasdaq
- OCUL Nasdaq
- Market Cap
- ARQT 1.1B
- OCUL 1.2B
- IPO Year
- ARQT 2020
- OCUL 2014
- Fundamental
- Price
- ARQT $13.02
- OCUL $7.00
- Analyst Decision
- ARQT Strong Buy
- OCUL Strong Buy
- Analyst Count
- ARQT 6
- OCUL 7
- Target Price
- ARQT $17.00
- OCUL $16.71
- AVG Volume (30 Days)
- ARQT 2.3M
- OCUL 917.6K
- Earning Date
- ARQT 02-25-2025
- OCUL 03-10-2025
- Dividend Yield
- ARQT N/A
- OCUL N/A
- EPS Growth
- ARQT N/A
- OCUL N/A
- EPS
- ARQT N/A
- OCUL N/A
- Revenue
- ARQT $138,708,000.00
- OCUL $61,442,000.00
- Revenue This Year
- ARQT $217.37
- OCUL $11.40
- Revenue Next Year
- ARQT $55.64
- OCUL $13.58
- P/E Ratio
- ARQT N/A
- OCUL N/A
- Revenue Growth
- ARQT 182.84
- OCUL 6.45
- 52 Week Low
- ARQT $6.99
- OCUL $4.06
- 52 Week High
- ARQT $16.20
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- ARQT 50.16
- OCUL 31.92
- Support Level
- ARQT $11.13
- OCUL $7.14
- Resistance Level
- ARQT $13.62
- OCUL $7.42
- Average True Range (ATR)
- ARQT 1.04
- OCUL 0.37
- MACD
- ARQT 0.08
- OCUL -0.02
- Stochastic Oscillator
- ARQT 67.26
- OCUL 0.76
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.